URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Yuchun Lee Biography and Net Worth

Director of Vertex Pharmaceuticals

Yuchun Lee is Co-Founder of Allego and has served as Chief Executive Officer of the Company since its inception in 2013. Mr. Lee is also the Executive Chairman of the Board of DSP Concepts, an Audio of Things (AoT) platform company. He is currently an executive in residence (XIR) at General Catalyst Partners, a venture capital firm, and also serves on the board of Vertex Pharmaceuticals (NASDAQ: VRTX), a Fortune 500 company. He was Executive Chairman of Clarabridge, Inc. until its successful acquisition by Qualtrics in 2021. Before founding Allego, Mr. Lee was the Vice President of IBM’s Enterprise Marketing Management Group, through a successful 2010 acquisition of Unica Corporation (NASDAQ: UNCA), an enterprise marketing management software company. Mr. Lee was Unica’s Chief Executive Officer from 1992 through 2010. Prior to Unica, he was a senior consultant at Digital Equipment Corporation, a supplier of general computing technology and consulting services. Mr. Lee holds a B.S. and an M.S. in electrical engineering and computer science from the Massachusetts Institute of Technology and an M.B.A. from Babson College.

What is Yuchun Lee's net worth?: The estimated net worth of Yuchun Lee is at least $765,337.50 as of January 27th, 2023. Mr. Lee owns 1,875 shares of Vertex Pharmaceuticals stock worth more than $765,338 as of December 25th. This net worth evaluation does not reflect any other assets that Mr. Lee may own. Learn More about Yuchun Lee's net worth.
How do I contact Yuchun Lee?: The corporate mailing address for Mr. Lee and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Yuchun Lee's contact information.
Has Yuchun Lee been buying or selling shares of Vertex Pharmaceuticals?: Yuchun Lee has not been actively trading shares of Vertex Pharmaceuticals during the last quarter. Most recently, Yuchun Lee sold 1,429 shares of the business's stock in a transaction on Friday, January 27th. The shares were sold at an average price of $322.03, for a transaction totalling $460,180.87. Following the completion of the sale, the director now directly owns 1,875 shares of the company's stock, valued at $603,806.25. Learn More on Yuchun Lee's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Yuchun Lee Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2023	Sell	1,429	$322.03	$460,180.87	1,875
1/25/2023	Sell	4,000	$313.96	$1,255,840.00	1,875
1/23/2023	Sell	2,129	$312.02	$664,290.58	1,875
1/18/2023	Sell	442	$312.17	$137,979.14	1,875
4/18/2022	Sell	2,000	$284.23	$568,460.00	1,875
4/13/2022	Sell	2,000	$287.50	$575,000.00	1,875
4/11/2022	Sell	2,000	$280.30	$560,600.00	1,875
4/7/2022	Sell	2,000	$274.86	$549,720.00	1,099
4/4/2022	Sell	2,000	$267.72	$535,440.00	1,875
4/27/2020	Sell	2,000	$271.21	$542,420.00	3,875
4/24/2020	Sell	2,000	$268.14	$536,280.00	3,875
4/22/2020	Sell	2,000	$267.88	$535,760.00	3,875
4/20/2020	Sell	2,000	$273.16	$546,320.00	3,875
2/7/2020	Sell	2,000	$237.82	$475,640.00	3,875
2/4/2020	Sell	2,000	$238.84	$477,680.00	3,875
1/4/2016	Sell	1,125	$122.21	$137,486.25	1,041
12/1/2015	Sell	1,125	$129.65	$145,856.25	833
11/2/2015	Sell	1,125	$126.19	$141,963.75	625
10/1/2015	Sell	1,125	$104.64	$117,720.00	416
9/1/2015	Sell	1,125	$125.40	$141,075.00	208

Yuchun Lee Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $408.18

$401.27

$410.68

50 Day Range

MA: $467.30

$396.64

$516.74

2 Week Range

Now: $408.18

$377.85

$519.88

Volume

1,468,555 shs

Average Volume

1,243,624 shs

Market Capitalization

$105.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW